The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study)
Titel:
The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study)
Auteur:
Deau, Bénédicte Nicolini, Franck E. Guilhot, Joelle Huguet, Françoise Guerci, Agnès Legros, Laurence Pautas, Cécile Berthou, Christian Guyotat, Denis Cony-Makhoul, Pascale Gardembas, Martine Michallet, Mauricette Hayette, Sandrine Cayuela, Jean Michel Weiss, Isabelle Radford Réa, Delphine Castaigne, Sylvie Mahon, François-Xavier Guilhot, François Rousselot, Philippe